NCT07154238Enrolling by invitation
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
Source: ClinicalTrials.gov · Last updated 25 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 2546 (estimated)
- First submitted
- 26 Aug 2025
- Start date
- 26 Sept 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT07154238
What you commit to
- Study type: Observational
- Planned participants: 2546
- From 26 Sept 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- For an eligible participant (HCPs), all exclusion criteria must be answered "no".
- Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview.
- Unwillingness or language barriers precluding adequate understanding or cooperation.
- Only treats patients under 18 years of age.
Other illness
- For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no".
- Unwillingness or language barriers precluding adequate understanding or cooperation.
- Is currently or planning to become pregnant in next six months.
- Is taking injectable semaglutide for Type 2 diabetes management only.
Who the study is looking for
- For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes".
- Electronically provided consent obtained before any study-related activities can be completed.
- Age above or equal to 18 years at the time of providing informed consent.
- Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain.
- Have been prescribed and initiated injectable semaglutide for weight management prior to study screening.
- For an eligible participant (HCPs), all inclusion criteria must be answered "yes".
- Electronically provided consent obtained before any study-related activities can be completed.
- Practice in a participating country: Australia, Germany, UAE, and Spain.
- See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month.
- Treat at least 10 adult patients per month for weight management.
- Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs).
- Prescribe injectable semaglutide for weight management.
- Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Bad Oeynhausen | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.